Urinary Bladder, Overactive: all 864 studies

Page 9 of 9. Open to participants first (125), then studies with results posted, then the rest; newest registration first within each.

• A Clinical Trial to Evaluate the Efficacy and Safety of DR-3001 in Women With Overactive BladderCompletedNCT00685113Phase 3
• Linkage Analysis in Interstitial CystitisCompletedNCT00675298
• Topical Oestrogens and Antimuscarinics In The Treatment Of Detrusor OveractivityCompletedNCT00648310Phase 2/3
• A Study to Evaluate the Efficacy of Tolterodine Prolonged Release Compared With Propiverine for the Treatment of Korean Patients With Overactive Bladder as Assessed by Ambulatory Urodynamic MonitoringCompletedNCT00646880Phase 3
• A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.CompletedNCT00645281Phase 4
• Non-Micturation Bladder Activity in Relation to Self-Consciousness During Filling Phase and Sensation Measurement During the Filling PhaseStatus unknownNCT00628615
• Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary IncontinenceCompletedNCT00603343Phase 3
• Autologous Neo-Bladder Construct in Non-Neurogenic Overactive Bladder and Urge Predominant IncontinenceWithdrawnNCT00594139Phase 2
• Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive BladderTerminatedNCT00578097Phase 2
• SSR240600C Treatment in Women With Overactive BladderCompletedNCT00564226Phase 2
• The Study To Test The Effect of Standardization Of Fluid Intake In Female Patients With Overactive BladderCompletedNCT00553657Phase 1
• Posterior Tibial Nerve Stimulation vs. ShamCompletedNCT00534521Phase 3
• A Study of YM178 in Patients With Symptomatic Overactive BladderCompletedNCT00527033Phase 2
• Long-term Safety and Efficacy of Imidafenacin in Patients With Overactive BladderCompletedNCT00512785Phase 3
• SVT-40776 in Patients Suffering From Overactive Bladder SyndromeCompletedNCT00507169Phase 2
• A Study To Test The Interaction of Two Medications for Treatment of Overactive BladderCompletedNCT00501267Phase 1
• Safety Study of hMaxi-K Gene Transfer to Treat Overactive Bladder and Detrusor OveractivityTerminatedNCT00495053Phase 1
• Evaluation of the Link Between Bladder Sensation and Changes in Skin Electrical Conductance and Heart Rate.CompletedNCT00481728Phase 1
• This is a Prospective, Randomized, Double-Blind Study Comparing Intravesical Injection of Botox® to Placebo.Status unknownNCT00479596Phase 2/3
• Study The Effects Of Different Doses Of UK-369,003 In Men With Overactive BladderCompletedNCT00479505Phase 2
• Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder SymptomsCompletedNCT00463541Phase 3
• A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB)CompletedNCT00454896Phase 3
• Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive BladderCompletedNCT00454740Phase 3
• Safety And Efficacy Of Solifenacin In Men With Overactive Bladder (OAB) And Detrusor UnderactivityCompletedNCT00441428
• ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)TerminatedNCT00439192Phase 2
• Safety and Applicability Study of a Novel Heat Flow Sensor Unit for Measuring Urinary Bladder CapacityStatus unknownNCT00437528
• A Two-Part Study to Determine: Best Medication Formulation and Food EffectCompletedNCT00427596Phase 1
• A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder PatientsCompletedNCT00368706Phase 3
• Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive BladderCompletedNCT00366002Phase 4
• Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder SymptomsCompletedNCT00343486Phase 2
• A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR)CompletedNCT00337558Phase 4
• A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)CompletedNCT00337090Phase 2
• Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor OveractivityTerminatedNCT00335660Phase 2
• Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury PatientsTerminatedNCT00332319Phase 2
• A Study Of GW679769 Compared To Placebo In Women With Overactive BladderCompletedNCT00321477Phase 2
• Assessing the OAB-8 Questionnaire as a Tool to Measure Treatment OutcomeStatus unknownNCT00313924Phase 4
• Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive BladderCompletedNCT00293839Phase 3
• Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)CompletedNCT00290563Phase 2
• Detrol LA In Men With Overactive Bladder.CompletedNCT00282932Phase 4
• Surface Nerve Stimulation Treatment for OAB in ChildrenCompletedNCT00282490Not applicable
• Botulinum-A Toxin Injection for Detrusor Hyperreflexia in Spinal Cord Injury: A Non-Surgical Approach.WithdrawnNCT00262496Phase 2
• Programmable Timer in the Bladder Rehabilitation Treatment of OABCompletedNCT00238680Not applicable
• A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007)CompletedNCT00231790Phase 2
• Efficacy and Safety of Botulinum Toxin A for the Treatment of Refractory Overactive Bladder.CompletedNCT00231491Phase 2
• Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.CompletedNCT00230789Phase 4
• Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive BladderCompletedNCT00224146Phase 4
• Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder SyndromeCompletedNCT00220402Phase 3
• Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension PhaseCompletedNCT00220389Phase 2
• Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder SyndromeCompletedNCT00220376Phase 3
• A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder SyndromeCompletedNCT00220363Phase 3
• NEUROTOX: Two Dosages of Type A Botulinic Toxin in Neurogenic Overactive BladderTerminatedNCT00213577Phase 2
• Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in JapanCompletedNCT00212732Phase 3
• Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in JapanCompletedNCT00212706Phase 2
• A Cost Analysis of Interstim TherapyCompletedNCT00200031
• Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive BladderCompletedNCT00196404Phase 2
• A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive BladderCompletedNCT00189800Phase 3
• MILADY: A Randomized, Placebo-controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence.CompletedNCT00174798Phase 2
• Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive BladderCompletedNCT00171184Phase 4
• A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.CompletedNCT00171145Phase 3
• A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive BladderCompletedNCT00170755Phase 3
• Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in WomenCompletedNCT00143481Phase 4
• Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder SyndromeCompletedNCT00138723Phase 3
• A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive BladderCompletedNCT00137397Phase 4
• Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive BladderCompletedNCT00127270Phase 4

← Urinary Bladder, Overactive overview